Last reviewed · How we verify

Systemic Cryptococcosis Treatment Adjunct — Treatment Landscape & Competitive Intelligence

Systemic Cryptococcosis Treatment Adjunct (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Systemic Cryptococcosis Treatment Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Ancobon FLUCYTOSINE Bausch Health Nucleoside Analog Antifungal [EPC] 5-hydroxytryptamine receptor 2A 1971-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bausch Health · 1 drug in Systemic Cryptococcosis Treatment Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Systemic Cryptococcosis Treatment Adjunct:

Cite this brief

Drug Landscape (2026). Systemic Cryptococcosis Treatment Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/systemic-cryptococcosis-treatment-adjunct. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing